Compare EVAX & MDBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVAX | MDBH |
|---|---|---|
| Founded | 2008 | 1997 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 29.0M |
| IPO Year | 2020 | 2022 |
| Metric | EVAX | MDBH |
|---|---|---|
| Price | $3.12 | $3.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | ★ 21.3K | 3.6K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $328.20 | N/A |
| P/E Ratio | ★ N/A | $4.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.45 | $2.45 |
| 52 Week High | $12.15 | $4.80 |
| Indicator | EVAX | MDBH |
|---|---|---|
| Relative Strength Index (RSI) | 44.53 | 56.29 |
| Support Level | $2.97 | $3.16 |
| Resistance Level | $3.61 | $3.57 |
| Average True Range (ATR) | 0.20 | 0.15 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 32.79 | 89.76 |
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The company operates in two reportable segments: a broker dealer & intellectual property service; and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.